Clinical and Trichoscopic Evaluations of Topical Finasteride 1%, Topical Spironolactone 5%, and Minoxidil 5% in Female Pattern Hair Loss Treatment
Introduction: Female pattern hair loss (FPHL) is one of the most common forms of diffuse alopecia in females.. Despite the availability of multiple treatment options, FPHL management poses challenges for the dermatologist. Objectives: We aimed to compare the efficacy and safety of topical finaste...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Mattioli1885
2025-01-01
|
| Series: | Dermatology Practical & Conceptual |
| Subjects: | |
| Online Access: | https://dpcj.org/index.php/dpc/article/view/4698 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832540721847992320 |
|---|---|
| author | Naglaa Mohamed El Sayed Eman Hamed Elmorsy Tarek Mahmoud Hussein Eman Hassan |
| author_facet | Naglaa Mohamed El Sayed Eman Hamed Elmorsy Tarek Mahmoud Hussein Eman Hassan |
| author_sort | Naglaa Mohamed El Sayed |
| collection | DOAJ |
| description |
Introduction: Female pattern hair loss (FPHL) is one of the most common forms of diffuse alopecia in females.. Despite the availability of multiple treatment options, FPHL management poses challenges for the dermatologist.
Objectives: We aimed to compare the efficacy and safety of topical finasteride 1% solution and spironolactone 5% solution to minoxidil 5% solution in the treatment of FPHL clinically and trichoscopically.
Methods: Forty-five adult female patients diagnosed with FPHL were divided into 3 groups of 15 each. Group A was treated with topical finasteride 1%, group B used topical spironolactone 5%, and group C was treated with topical minoxidil solution 5 %, for 16 weeks.
Results: By the end of 16th week, significant improvement in the Sinclair scale was observed in groups A and C, but the difference between the 3 groups was statistically insignificant. Trichoscopically, hair density significantly increased in groups A and C. There was a significant reduction in the number of patients with yellow dots, peripilar sign, as well as single hair follicular units (FU) in group A. In group C, a significant reduction in number of patients with yellow dots and single hair FU was documented. No trichoscopic changes were detected in group B.
Conclusions: Topical finasteride is as safe and effective as topical minoxidil in FPHL. Both treatments showed higher efficacy clinically and trichoscopically than topical spironolactone. The use of topical finasteride may be another solution for the treatment of FPHL in minoxidil non-responders or in the presence of intolerable side effects
|
| format | Article |
| id | doaj-art-596e9f49c813461f9946997e0515acea |
| institution | Kabale University |
| issn | 2160-9381 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Mattioli1885 |
| record_format | Article |
| series | Dermatology Practical & Conceptual |
| spelling | doaj-art-596e9f49c813461f9946997e0515acea2025-02-04T15:41:37ZengMattioli1885Dermatology Practical & Conceptual2160-93812025-01-0115110.5826/dpc.1501a4698Clinical and Trichoscopic Evaluations of Topical Finasteride 1%, Topical Spironolactone 5%, and Minoxidil 5% in Female Pattern Hair Loss TreatmentNaglaa Mohamed El Sayed0Eman Hamed Elmorsy1Tarek Mahmoud Hussein2Eman Hassan3Department of Dermatology, Venereology and Andrology, Faculty of Medicine, Alexandria University, Alexandria, EgyptDepartment of Dermatology, Venereology and Andrology, Faculty of Medicine, Alexandria University, Alexandria, EgyptDepartment of Dermatology, Venereology and Andrology, Faculty of Medicine, Alexandria University, Alexandria, EgyptDepartment of Dermatology, Venereology and Andrology, Faculty of Medicine, Alexandria University, Alexandria, Egypt Introduction: Female pattern hair loss (FPHL) is one of the most common forms of diffuse alopecia in females.. Despite the availability of multiple treatment options, FPHL management poses challenges for the dermatologist. Objectives: We aimed to compare the efficacy and safety of topical finasteride 1% solution and spironolactone 5% solution to minoxidil 5% solution in the treatment of FPHL clinically and trichoscopically. Methods: Forty-five adult female patients diagnosed with FPHL were divided into 3 groups of 15 each. Group A was treated with topical finasteride 1%, group B used topical spironolactone 5%, and group C was treated with topical minoxidil solution 5 %, for 16 weeks. Results: By the end of 16th week, significant improvement in the Sinclair scale was observed in groups A and C, but the difference between the 3 groups was statistically insignificant. Trichoscopically, hair density significantly increased in groups A and C. There was a significant reduction in the number of patients with yellow dots, peripilar sign, as well as single hair follicular units (FU) in group A. In group C, a significant reduction in number of patients with yellow dots and single hair FU was documented. No trichoscopic changes were detected in group B. Conclusions: Topical finasteride is as safe and effective as topical minoxidil in FPHL. Both treatments showed higher efficacy clinically and trichoscopically than topical spironolactone. The use of topical finasteride may be another solution for the treatment of FPHL in minoxidil non-responders or in the presence of intolerable side effects https://dpcj.org/index.php/dpc/article/view/4698finastreidespironolactoneFPHL |
| spellingShingle | Naglaa Mohamed El Sayed Eman Hamed Elmorsy Tarek Mahmoud Hussein Eman Hassan Clinical and Trichoscopic Evaluations of Topical Finasteride 1%, Topical Spironolactone 5%, and Minoxidil 5% in Female Pattern Hair Loss Treatment Dermatology Practical & Conceptual finastreide spironolactone FPHL |
| title | Clinical and Trichoscopic Evaluations of Topical Finasteride 1%, Topical Spironolactone 5%, and Minoxidil 5% in Female Pattern Hair Loss Treatment |
| title_full | Clinical and Trichoscopic Evaluations of Topical Finasteride 1%, Topical Spironolactone 5%, and Minoxidil 5% in Female Pattern Hair Loss Treatment |
| title_fullStr | Clinical and Trichoscopic Evaluations of Topical Finasteride 1%, Topical Spironolactone 5%, and Minoxidil 5% in Female Pattern Hair Loss Treatment |
| title_full_unstemmed | Clinical and Trichoscopic Evaluations of Topical Finasteride 1%, Topical Spironolactone 5%, and Minoxidil 5% in Female Pattern Hair Loss Treatment |
| title_short | Clinical and Trichoscopic Evaluations of Topical Finasteride 1%, Topical Spironolactone 5%, and Minoxidil 5% in Female Pattern Hair Loss Treatment |
| title_sort | clinical and trichoscopic evaluations of topical finasteride 1 topical spironolactone 5 and minoxidil 5 in female pattern hair loss treatment |
| topic | finastreide spironolactone FPHL |
| url | https://dpcj.org/index.php/dpc/article/view/4698 |
| work_keys_str_mv | AT naglaamohamedelsayed clinicalandtrichoscopicevaluationsoftopicalfinasteride1topicalspironolactone5andminoxidil5infemalepatternhairlosstreatment AT emanhamedelmorsy clinicalandtrichoscopicevaluationsoftopicalfinasteride1topicalspironolactone5andminoxidil5infemalepatternhairlosstreatment AT tarekmahmoudhussein clinicalandtrichoscopicevaluationsoftopicalfinasteride1topicalspironolactone5andminoxidil5infemalepatternhairlosstreatment AT emanhassan clinicalandtrichoscopicevaluationsoftopicalfinasteride1topicalspironolactone5andminoxidil5infemalepatternhairlosstreatment |